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Background: An implantable port device provides an easily accessible central route for long-term chemotherapy.
Venous catheter migration is one of the rare complications of venous port implantation. It can lead to side effects
such as pain in the neck, shoulder, or ear, venous thrombosis, and even life-threatening neurologic problems.
To date, there are few published studies that discuss such complications.
Methods: This retrospective study of venous port implantation in a single center, a Taiwan hospital, was conducted
from January 2011 to March 2013. Venous port migration was recorded along with demographic and characteristics
of the patients.
Results: Of 298 patients with an implantable import device, venous port migration had occurred in seven, an
incidence rate of 2.3%. All seven were male and had received the Bard port Fr 6.6 which had smaller size than
TYCO port Fr 7.5 and is made of silicon. Significantly, migration occurred in male patients (P = 0.0006) and in those
with lung cancer (P = 0.004). Multivariable logistic regression analysis revealed that lung cancer was a significant risk
factor for port migration (odds ratio: 11.59; P = 0.0059). The migration rate of the Bard port Fr 6.6 was 6.7%. The
median time between initial venous port implantation and port migration was 35.4 days (range, 7 to 135 days) and
71.4% (5/7) of patients had port migration within 30 days after initial port implantation.
Conclusions: Male sex and lung cancer are risk factors for venous port migration. The type of venous port is also
an important risk factor.
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Venous port implantation is widely used for the safe de-
livery of systemic chemotherapy in patients with cancer.
However, various complications have been documented
and the total complication rate ranges from 0.4% to 29%
[1-6]. Catheter migration is a rare complication with an
unknown cause that occurs in about 0.9 to 2% of patients
[3,5,7,8]. It can lead to side effects such as pain in the
neck, shoulder, or ear, venous thrombosis [9-12], and even
life-threatening neurologic problems [13-15]. Because of* Correspondence: chjeya@cc.kmu.edu.tw
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reproduction in any medium, provided the orits rarity, very few studies have been published that exten-
sively tackled venous catheter migration [3,7]. This retro-
spective study is an investigation of venous port migration
in a hospital in Taiwan. Related literature is also reviewed.Methods
All patients who underwent venous port implantation
(BardPort® 6.6 Fr implantable port, NJ, USA (Bard port)
or Autosuture Chemosite® Fr 7.5, Tyco healthcare group,
Connecticut, USA (TYCO port)) for chemotherapy at
Kaohsiung Municipal Ta-Tung Hospital between 1 January
2011 and 31 March 2013, were retrospectively eva-
luated. The Bard port® was made of silicon while the
Autosuture Chemosite® was made of polyurethane (PU).
The procedures were all performed by an experienced
surgeon (Dr. WC Fan) under local anesthesia. The ves-
sel cut-down method was used for catheter cannulation.. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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controlled and the catheter was inserted via the superior
vena cava. The cephalic vein was the first choice for entry
exploration and occasionally, the subclavian vein was the
point of entry if the cephalic vein was difficult to access.
All locations of the implanted venous ports were con-
firmed by fluoroscopy and post-operative x-rays. The sur-
geon ensured that all of the tips of the venous catheters
were located at the junction of the superior vena cava and
right atrium (cavo-atrial junction) intra-operatively. The
cavo-atrial junction was the point at which the superior
vena cava met and joined the superior wall of the right
atrium. For purposes of radiographic visualization, the most
reliable indicators of the junction were the carina and the
overlying vertebrae. The junction lay two vertebral body
units below the carina [16].
The term ‘venous port migration’ referred to a venous
port that was not in the correct position. This was diag-
nosed based on chest x-ray taken before the course of
chemotherapy in a patient (Figure 1). The Institutional
Review Board of Kaohsiung Medical University Hospital
approved this study.
Data were entered and analyzed using the JMP statistical
software (version 9.0, SAS Institute Inc., Cary, NC, USA).
Demographic data, underlying cancer, and related covari-
ates were compared between the group with and without
port migration using the Fisher’s exact test for categorical
variables or Wilcoxon rank sum test for continuous vari-
ables. To identify the major factors associated with port
migration, multivariable logistic regression was performed.
Statistical significance level was set at P < 0.05.
Results
A total of 298 patients with mean (± standard deviation)
age of 61.4 ± 12.3 years were enrolled. Among them, 145Figure 1 A 48-year-old man who underwent (A) venous port implanta(48.7%) were male (Table 1). Moreover, 104 patients re-
ceived the Bard port and 194 received the TYCO port.
The patients who received the Bard port implantation
were older, with male predominance. More patients in the
Bard port group received their port through the right side
via the cephalic vein. In terms of port migration, the Bard
port had a significantly higher migration rate, up to 6.7%,
compared to 0% of the TYCO port (P = 0.0006).
Based on the occurrence of port migration, the pa-
tients were further classified into the migration group
and non-migration group (Table 2). The mean age and
mean body mass index (BMI) did not differ significantly
between the two groups. Venous port migration oc-
curred in only seven patients in this retrospective study.
All of them were male, used the Bard port, and received
their port via the cephalic vein. Five (71.4%) of them
were lung cancer patients.
Multivariable logistic regression analysis of the factors
related to port migration revealed that lung cancer was a
significant risk factor for port migration (odds ratio (OR):
11.59, 95% confidence interval (CI): 2.25 to 87.73; P =
0.0059). Sex and venous port type were not included in
the model because all of the patients in the migration
group were male and had been fitted with the Bard port
(Table 3).
The median time between initial venous port implant-
ation and port migration was 35.4 days (range, 7 to 135
days), 71.4% of which occurred within 30 days after ini-
tial port implantation.
There were no complications associated with the port
migration as it was promptly detected before intraven-
ous chemotherapy was administered. All of the patients
successfully underwent surgical revision of the venous
port and no recurrence of port migration was noted till
the end of the study.tion experienced (B) catheter migration after 21 days.
Table 1 Baseline characteristics of the patients using different ports
All patients Bard port TYCO port P value
n % n % n %
Patient number 298 104 194
Age 0.0116
mean ± standard deviation 61.4 ± 12.3 63.9 ± 11.3 60.1 ± 12.7
median (inter-quartile range) 61 (54 to 70.8) 63.1 (56.3 to 72) 60 (51 to 69)
Sex 0.0034
Female 153 51.3% 41 39.4% 112 57.7%
Male 145 48.7% 63 60.6% 82 42.3%
Body mass index 0.1077
mean ± standard deviation 24.2 ± 6.8 23.4 ± 3.6 24.7 ± 8.0
medium (inter-quartile range) 23.6 (21.1 to 26.4) 23.4 (21.1 to 25.4) 23.9 (21.0 to 26.7)
Migration 0.0006
No 291 97.7% 97 93.3% 194 100.0%
Yes 7 2.3% 7 6.7% 0 0.0%
Side < 0.0001
Left 97 32.6% 19 18.3% 78 40.2%
Right 201 67.5% 85 81.7% 116 59.8%
Entering vessel < 0.0001
Cephalic vein 261 87.6% 102 98.1% 159 82.0%
Subclavian vein 37 12.4% 2 1.9% 35 18.0%
Malignancy (indication for the port)
Head and neck tumor 17 5.7% 4 3.9% 13 6.7%
Lung cancer 59 19.8% 32 30.8% 27 13.9%
Esophageal cancer 2 0.7% 0 0.0% 2 1.0%
Breast cancer 55 18.5% 4 3.9% 51 26.3%
Gastric cancer 14 4.7% 7 6.7% 7 3.6%
Colorectal cancer 64 21.5% 29 27.9% 35 18.0%
Hepatobiliary and pancreatic tumor 8 2.7% 3 2.9% 5 2.6%
Ovary cancer and cervical cancer 26 8.7% 7 6.7% 19 9.8%
Urological cancer 37 12.4% 12 11.5% 25 12.9%
Leukemia and lymphoma 11 3.7% 3 2.9% 8 4.1%
Other malignancy 3 1.0% 1 1.0% 2 1.0%
Malnutrition, no malignancy 2 0.7% 2 1.9% 0 0.0%
Lung cancer 0.0007
Yes 59 19.8% 32 30.8% 27 13.9%
No 239 80.2% 72 69.2% 167 86.1%
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This report demonstrates that the type of venous port
may lead to different migration rates. Moreover, male sex
and lung cancer patients also have significantly higher mi-
gration rates.
An implantable port device provides easy access for
long-term chemotherapy. A recent retrospective analysisof more than 3,000 chest-port placements by interven-
tional radiologists provides a good analysis of outcomes,
including a nearly 100% technical success rate and an
overall complication rate of 11.8% (1.3% peri-procedural,
3.3% early, and 9.4% late complications) [17]. Early com-
plications include pneumothorax, hematoma, malposition,
embolism, or arrhythmia, which are often related to the
Table 2 Characteristics of the patients with and without port migration
Migration group Non-migration group P value
n % n %
Patient number 7 291
Age 0.1181
mean ± SD 68.1 ± 10.7 61.2 ± 12.4
median (inter-quartile range) 71 (62 to 74) 61 (54 to 70.3)
Gender 0.0060
Female 0 0.0% 153 52.6%
Male 7 100.0% 138 47.4%
Body mass index 0.3211
mean ± standard deviation 24.9 ± 1.8 24.2 ± 6.9
medium (inter-quartile range) 24.7 (23.3 to 26.9) 23.6 (21 to 26.4)
Venous port type 0.0006
Bard Fr 6.6 7 100.0% 97 33.3%
TYCO Fr 7.5 0 0.0% 194 66.7%
Side 0.4338
Left 1 14.3% 96 33.0%
Right 6 85.7% 195 67.0%
Entering vessel 0.6025
Cephalic vein 7 100.0% 254 87.3%
Subclavian vein 0 0.0% 37 12.7%
Malignancy (indication for the port)
Head and neck tumor 0 0.0% 17 5.8%
Lung cancer 5 71.4% 54 18.6%
Esophageal cancer 0 0.0% 2 0.7%
Breast cancer 0 0.0% 55 18.9%
Gastric cancer 1 14.3% 13 4.5%
Colorectal cancer 0 0.0% 64 22.0%
Hepatobiliary and pancreatic tumor 0 0.0% 8 2.7%
Ovary cancer and cervical cancer 0 0.0% 26 8.9%
Urological cancer 0 0.0% 37 12.7%
Leukemia and lymphoma 1 14.3% 10 3.4%
Other malignancy 0 0.0% 3 1.0%
Malnutrition, no malignancy 0 0.0% 2 0.7%
Lung cancer 0.0040
Yes 5 71.4% 54 18.6%
No 2 28.6% 237 81.4%
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necrosis, infection, catheter fracture, occlusion, throm-
bosis, and migration [1,2,6-8,17].
Infectious and thrombotic issues dominate port compli-
cations. The reported rates of long-term venous access in-
fections range from 0.6% to 27% and depend on catheter
location, catheter type, and patient’s immune status [18].
Spontaneous venous port migration is rare and occurs in
about 0.9 to 2% of patients, according to published articles[3,5,7,8]. In one study, the indicated incidence of catheter
migration is about 0.04/1,000 catheter days.
In fluoroscopy-assisted port catheter implantation, pri-
mary migration (intra-operative) of the catheter tip is rare
but secondary migration (post-operative) may occur due
to high intra-thoracic pressure, arm movement, or other
unknown causes. This current study reveals a similar inci-
dence of venous port migration of 2.34%. However, there
is a significantly higher incidence of venous port migration
Table 3 Multivariable logistic regression analysis of
factors affecting port migration
Variables Odds Ratio 95% CI P value
All study subjects
Age > 60 versus age≤ 60 4.85 (0.77 to 94.61) 0.1542
BMI≥ 24 versus BMI < 24 2.60 (0.50 to 15.34) 0.2578
Right versus left 2.15 (0.31 to 42.73) 0.4980
Lung cancer versus others 11.59 (2.25 to 87.73) 0.0059
Patients using Bard port
Age > 60 versus age≤ 60 4.28 (0.64 to 86.22) 0.2019
BMI≥ 24 versus BMI < 24 2.46 (0.47 to 14.54) 0.2877
Right versus left 1.22 (0.16 to 25.72) 0.8638
Lung cancer versus others 7.59 (1.47 to 58.03) 0.0235
Male patients
Age > 60 versus age≤ 60 3.35 (0.51 to 68.47) 0.2826
BMI≥ 24 versus BMI < 24 2.45 (0.47 to 14.56) 0.2911
Right versus left 2.27 (0.33 to 45.38) 0.4704
Lung cancer versus others 7.03 (1.37 to 53.15) 0.0283
Lung cancer patients
Age > 60 versus age≤ 60 2.59 (0.34 to 53.55) 0.4152
BMI≥ 24 versus BMI < 24 1.65 (0.19 to 12.53) 0.6216
Right versus left 1.32 (0.14 to 28.65) 0.8201
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the Autosuture Chemosite® Fr 7.5. Some reasons can be
posited. The smaller caliber port (Bardport® Fr 6.6) may be
more flexible and have more potential of migrating to the
ipsilateral internal jugular vein. Furthermore, BardPort® is
made of silicon whereas the Autosuture Chemosite® is
made of PU. Silicon is more flexible than PU and this may
account for the higher migration rate.
In a report of Wu et al., there is no difference between
any port types. However, the incidence of migration in the
Bard Fr 6.6 is as high as 3.69% (15/406), much higher than
that of other types [3].
The most common migration site is the internal ju-
gular vein. Sometimes, catheters migrate to the peri-
cardiophrenic vein and cause cardiac tamponade [19].
Cough-induced port migration to the right axillary vein
has also been reported. Other migration/malposition sites
are the left subclavian vein, right internal thoracic vein,
inferior thyroid vein, left brachial vein, and right brachio-
cephalic vein. All of the seven cases involve catheter migra-
tion into the ipsilateral internal jugular vein. In addition, a
high infusion flow rate can also make the tip migrate.
Wu et al. have stated that shallow catheter-tip location
and the presence of lung cancer are risk factors for catheter
migration. Strategies that ensure low catheter-tip location
and avoid increased thoracic pressure may be useful pre-
ventive measures [3]. Once migration is detected, promptcorrection is important. A catheter tip position in the right
atrium or ventricle may cause cardiac arrhythmia, perfor-
ation, tamponade, or thrombosis. When the central venous
catheter tip is located in an undesirable site, the injected
drugs or fluid will also directly enter a small caliber vein
and subsequently induce complications like neck pain,
shoulder pain, ear pain, venous phlebitis, or thrombosis.
Some venous port migrations have been detected following
chest x-ray in patients who complain of right neck pain.
The inadvertent infusion of irritant drugs may be life-
threatening if neurologic complications and cortical vein
thrombosis occur [13,14]. Fortunately, no complications
developed in the study period because each migration
event was promptly detected prior to chemotherapy.
The mechanism of venous port migration remains un-
clear but physical forces acting on the catheter has been
proposed, including increased intra-thoracic pressure
due to coughing, sneezing, or weight lifting, changes in
body position, or physical movements like abduction or
adduction of the arms or hyper-extension of the shoul-
der [3,10]. Among these possible mechanisms, cough is
the most common in several case reports [12]; severe
cough can generate up to 300 mmHg of intra-thoracic
pressure against a closed glottis, followed by forceful ex-
pulsion of air and secretions via the glottic opening.
Vigorous changes in intra-thoracic pressure may result
in herniation of a short segment of the shaft of the cath-
eter into the jugular vein [20]. Repeated cough may cause
progressive herniation and eventually complete the caudal
migration of the catheter tip [3]. Moreover, cough is the
most common symptom in patients with lung cancer. This
hypothesis may explain why, in the study by Wu et al. and
in the present study, lung cancer patients have a higher in-
cidence of migration than other cancers. A high infusion
flow rate can also lead to tip migrate, as reported.
In the current study, venous port migrations occur early
after implantation. In a swine model, central venous cathe-
ters have a partial or circumferential mixed cellular and
non-cellular covering consisting of smooth muscle cells,
thrombus, and areas with endothelial cell populations. Less
prominent cellularity and more prominent collagen con-
tent develop after 30 to 45 days. With longer catheter in-
dwelling time, an endothelial layer, indistinguishable from
the adjacent vein wall, covers the catheter surface [21].
The experiment may explain why migration occurs within
30 days in most of the patients in the present study.
Once migration is detected, prompt revision is import-
ant to avoid complications. Re-positioning through ei-
ther surgery-based revision or radiologic interventional
procedure shows very high initial success rates [7,12,22].
The trans-femoral snaring technique is also a quick and
easy method to re-position the catheter tip [23].
A limitation of this study is its small case number;
therefore further large-scale studies are warranted.
Fan et al. World Journal of Surgical Oncology 2014, 12:15 Page 6 of 6
http://www.wjso.com/content/12/1/15Conclusion
This is the first study to report that the type of venous
port may affect the port migration rate. Male sex and lung
cancer patients also have significantly higher migration
rates. Port migration often occurs within 30 days after the
initial implantation. Periodic check-ups by chest X-ray of
catheter location are crucial for detecting catheter tip mi-
gration and for early intervention to prevent potential
complications.
Abbreviation
BMI: Body mass index.
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